There are some hard limits to the vaccine development process that mean we are not going to see any preventative immune therapies to fight the new coronavirus for at least a year to 18 months. Darrell Etherington reports in Techcrunch, however, that Moderna, which is behind the first potential vaccine to enter human clinical trials in the U.S., provided new info on Monday that indicates it will seek to provide access to the vaccine to a limited group, likely consisting of healthcare workers, by as early as this fall.